Clinical Study Results

• MOBIC ® - Respiratory Tract Infections

  Clinical Study Number	107.250
  Study Indication	Respiratory Tract Infections
  Product	MOBIC ®
  Generic Name	Meloxicam
  Lab Code
  Clinical Phase	IV
  Study Title	Randomized, open-label, controlled trial to assess the clinical efficacy and safety of meloxicam suspension 0.25 mg/kg/day once a day, versus diclofenac 1 mg/kg/day twice a day or nimesulide 4 mg/kg/day twice a day, for five days in the treatment of patients with acute, non-bacterial pharyngitis, pharyngotonsillitis or laryngitis
  Study Document	Trial synopsis 107.250 english